| Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome. | |
| | |
MedLine Citation:
|
PMID: 11865968 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The pharmacokinetics (PK) and safety of fluvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, were assessed in subjects with renal impairment and nephrotic syndrome. In a single-center, open-label, parallel-group study, a single dose of fluvastatin 40 mg was administered to subjects (8 per group, n = 48) with nephrotic syndrome (group II), healthy subjects (group I), and subjects with various degrees of renal impairment (groups III to VI). Subjects undergoing hemodialysis received two doses, one 2 days before and one just prior to hemodialysis. Blood samples to determine the PK parameters of fluvastatin were collected from 0 to 12 hours after drug intake. Noncompartmental PK evaluation and statistical analysis (descriptive and ANOVA) were performed. Safety was evaluated and vital signs were monitored. There was no difference in the PK parameters AUC0-infinity and Cmax of fluvastatin between healthy subjects and subjects with renal impairment. Fluvastatin was not removed from plasma by hemodialysis. In patients with nephrotic syndrome, the values for AUC0-infinity and Cmax were less than half of those obtained in the other groups; terminal half-life values, however, were comparable. Fluvastatin was well tolerated in all study participants. Only few adverse events of mild to moderate intensity were reported. There were no clinically relevant changes in laboratory parameters in the subjects with renal impairment. Renal impairment did not affect the PK of fluvastatin after a single oral dose. Exposure to fluvastatin was lower in subjects with nephrotic syndrome. Fluvastatin also was well tolerated in subjects with nephrotic syndrome. |
| | |
Authors:
|
S Appel-Dingemanse; T Smith; M Merz |
Related Documents
:
|
865128 - Nephrotic syndrome associated with gastric cancer. 309658 - Hemophilus influenzae f cellulitis with bacteremia, peritonitis, and pleuritis in an ad... 9617498 - A case of immunotactoid glomerulopathy with unusual microtubular deposits. 9926248 - Rare syndromes in hodgkin's disease. 19003908 - A case of moyamoya syndrome and hemoglobin e/beta-thalassemia. 17993428 - Current practice in the use of nerve conduction studies in carpal tunnel syndrome by su... |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Journal of clinical pharmacology Volume: 42 ISSN: 0091-2700 ISO Abbreviation: J Clin Pharmacol Publication Date: 2002 Mar |
Date Detail:
|
Created Date: 2002-02-27 Completed Date: 2002-09-06 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0366372 Medline TA: J Clin Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 312-8 Citation Subset: IM |
Affiliation:
|
Novartis Pharma AG, Basel, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Analysis of Variance Area Under Curve Fatty Acids, Monounsaturated / adverse effects, blood, pharmacokinetics*, therapeutic use Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects, blood, pharmacokinetics*, therapeutic use Indoles / adverse effects, blood, pharmacokinetics*, therapeutic use Kidney Failure / blood*, drug therapy Middle Aged Nephrotic Syndrome / blood*, drug therapy Renal Dialysis / statistics & numerical data |
| Chemical | |
Reg. No./Substance:
|
0/Fatty Acids, Monounsaturated; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Indoles; 93957-54-1/fluvastatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of calcineurin inhibitor therapy on P-gp expression and function in lymphocytes of renal tran...
Next Document: A comparison of methods for assessing hypothalamic-pituitary-adrenal (HPA) axis activity in asthma p...